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Abstract
Background: Health Related Quality of Life (HRQoL) is an important outcome measure in
Inflammatory Bowel Disease (IBD). The aim of our study was to assess HRQoL in a population of
135 Greek patients with IBD.
Methods: A cohort of 135 patients with IBD, 81 with ulcerative colitis (UC) and 54 with Crohn's
disease (CD) were enrolled in our study. Demographic and disease-related data were recorded.
HRQoL was assessed by a disease-specific and a generic questionnaire, IBDQ and SF-36,
respectively. Disease activity was assessed by Harvey-Bradshaw Index and the Colitis Activity Index
for CD and UC patients, respectively.
Results: Among all variables recorded in our study, only disease activity had a significant effect on
HRQoL. Patients with active disease scored significantly lower on both IBDQ and SF-36 when
compared to those in remission. Only two among the four IBDQ dimensions, bowel and systemic,
had significant ability in distinguishing best patients in remission from those with active disease.
Conclusions: IBD has a negative impact on HRQoL. Patients with active disease are more
impaired than patients in remission. In our population of patients bowel and systemic dimensions
had a predominant value in patients' perception of quality of life. Patients in our study using the
same instrument scored higher than previously reported.
Background
Inflammatory Bowel Diseases [Ulcerative Colitis (UC),
Crohn's Disease (CD)] are chronic diseases of the alimen-
tary tract, that can commence at any time during life but
their highest incidence occurs between 15 and 35 years of
age. They have a great impact during a very active period
of life that often includes acquiring an education, devel-
oping a career and raising a family [1]. The prevalence of
IBD in Europe is 160–320 patients per 100.000 inhabit-
ants and the incidence is around 16 new cases per 100.000
of population [2,3].
Traditionally treatment and follow-up of patients with In-
flammatory Bowel Disease (IBD) is mainly based on clin-
ical symptoms, laboratory tests, endoscopic and
histologic findings. However these findings fail to reflect
the patients' subjective experience of health [4,5].
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Most patients need continuous medication and long term
medical follow-up. The long term outcome of IBD today,
with better treatment has improved considerably. The life
expectancy is equal to those of people of the same age and
sex [6,7]. The majority of patients are able to lead a nor-
mal social, family and professional life [1]. However IBD
patients do have an impaired quality of life, with physical,
social and emotional dysfunction, which is not necessari-
ly examined using the traditional clinical approach [8–
12].
A more comprehensive assessment may be provided by
complementing the traditional measures of disease activ-
ity with measures of the patients' perceptions of their dis-
ease and received care. Such an approach may result into
a better understanding of the patients' global situation
and the many difficulties they experience due to their dis-
ease. This approach should contribute to better patient
care.
The aim of our study was to assess the Health Related
Quality of Life (HRQoL) in a population of unselected
Greek patients with IBD, by using a validated disease-spe-




One hundred and fifty-one IBD, consecutive, non-select-
ed, patients fulfilling the Lennard-Jones criteria [13] were
enrolled in the study. All patients gave prior informed
consent. The great majority of our patients came from our
outpatients' clinic. Some patients were hospitalized at the
time of HRQoL assessment. Outpatients had the ques-
tionnaires administered to them at their follow-up visit
and hospitalized patients within the first two days of their
hospitalization. Patients with an ileostomy were excluded
from the study.
Demographic data collected included age, gender, marital
status and smoking habits. Data regarding the disease in-
cluded disease duration, age at first diagnosis of disease,
and disease activity.
From the original 151 patients 7 (4.6%) refused to partic-
ipate in the study and 9 (6.0%) patients were excluded be-
cause of contradicting answers in the questionnaire. Thus
the study comprised 135 IBD patients, 81 (60%) with UC
and 54 (40%) with CD. Excluded patients were compared
with those included and no significant differences were
found regarding the demographic data. Patient character-
istics are shown in table 1.
HRQoL Assessment
The Inflammatory Bowel Disease Questionnaire is an in-
terviewer administered, disease-specific questionnaire. It
was developed and validated by Guyatt et al [14]. It con-
tains 32 questions, which are divided into four health do-
mains: bowel symptoms (10 questions), systemic
symptoms (5 questions), emotional function (12 ques-
tions), and social function (5 questions). For each ques-
tion there are graded responses on a 7-point Likert scale,
ranging from 1 (representing the "worst" aspect) to 7 (rep-
resenting the "best" aspect). Thus, the total IBDQ score
ranges from 32 to 224, with higher scores reflecting better
well-being. Subsequent validation of the IBDQ yielded a
strong correlation with disease severity (r = -0.5; p <
0.001) and a test-retest reliability coefficient of 0.7
[14,15]. Mean score changes of 16 to 30 points have been
linked to changes in therapy. Statistically significant dif-
ferences also occur between active and inactive disease
[14–17]. The IBDQ has been translated and validated in a
cohort of 114 Greek IBD patients and proved to be a valid
and reliable instrument [18]. The IBDQ has been translat-
ed and validated in Dutch, English, Spanish and Korean
[19–24]. A self-administered version and a shortened ver-
sion of the IBDQ have also been validated [25,26]. HR-
QoL was also assessed by a non-disease-specific
questionnaire, the Short Form Health Survey (SF-36) [27–
30]. The SF-36 is a widely used generic instrument, which
has been used in Greek patients; results related to a study
with IBD patients have been reported previously [18]. It
consists of 36 questions grouped into eight dimensions:
'physical function' (10 items), 'role limitations due to
physical health problems' (4 items), 'bodily pain' (2
items), 'general health perception' (6 items), 'energy and
vitality' (4 items), 'social function' (2 items), 'role limita-
tions due to emotional problems' (3 items), and 'mental
health' (5 items) [27–30]. Each of the dimension scores is
expressed as a value between 0 and 100, with higher
scores representing better health. In order to have a valid
comparison with IBDQ, the above eight dimensions were
converted into four corresponding to the IBDQ dimen-
sions. In this conversion 'bodily pain' represents bowel
symptoms; 'health perception' and 'energy and vitality'
represent systemic symptoms; 'physical function', 'role
limitations due to physical health problems', and 'social
function' represent social function; 'role limitations due
to emotional problems' and 'mental health' represent
emotional function [18,20,22]. Both questionnaires were
administered during a patient interview, by a physician
(AGP) who was not the treating doctor.
Disease Activity
Disease activity in CD patients was assessed by the Harvey
Bradshaw Index (HBI) [31], which includes general well-
being, abdominal pain, daily number of watery stools,
complications and abdominal mass, while in UC patientsBMC Gastroenterology 2002, 2 http://www.biomedcentral.com/1471-230X/2/1
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was assessed by using the colitis activity index (CAI) [32].
The CAI includes 6 symptoms: general well-being, ab-
dominal tenderness, pain or cramping, fecal inconti-
nence, daily and nocturnal diarrhea, and visible blood in
stool. This was chosen because it relies entirely on symp-
toms and does not require invasive procedures. Total
scores range from 0 to 21, with scores less than 10 indicat-
ing remission. Patients were classified as having 'no or mi-
nor symptoms' (HBI score 1–5 for patients with CD and
CAI score less than 10 for patients with UC) and 'severe
symptoms' (HBI more than 5 for CD and CAI more than
10 for UC) [18].
Statistical Analysis
Descriptive statistics are reported as mean, standard devi-
ation, median, and range. Statistical comparisons be-
tween the two groups were made either by Pearson χ 2-test
(for proportions) or by Student's t-test (for means). Com-
parisons involving two grouping factors were made by
two-way analysis of variance. [33]. The independent influ-
ence of a number of demographic and clinical factors on
HRQoL (total or dimensional IBDQ scores) was assessed
by multiple linear regression; this was used stepwise
(backward elimination of variables). The relative per-
formance of the four IBDQ dimensions in distinguishing
best patients with minor symptoms from those with se-
vere, was studied by discriminant analysis. This method
also was applied stepwise (backward elimination) [34].
Reclassification of observations was effected by cross-vali-
dation (leaving-one-out) method [35]; this method is
known to provide unbiased re-classification results.
Results
There was a predominance of men in the whole study
population (male to female ratio = 1:0.63) and similarly
in each of the two disease groups (male to female ratio =
1:0.76 for UC and 1:0.46 for CD). The proportion of fe-
males in the UC group (43.2%) was higher than in the CD
group (31.5%), but not significantly different (p = 0.17).
The median age of patients with UC did not differ signifi-
cantly (p = 0.424) from that of patients with CD (median
age 41 vs 39). As expected [36–43] the pattern of smoking
habits was different in UC group compared to CD group.
There was a predominance of non-smokers (62.3%) and
ex-smokers (21.3%) among the UC patients compared to
those among CD patients (37.8% and 17.8%, respective-
ly) (p = 0.006). The mean duration of disease was 8.4
years for UC (range 0.1–38.0) and 6.5 years for CD (range
0.2–30.0); the difference was not significant (p = 0.187).
Disease activity as measured by CAI for UC and HBI for
CD, was generally low, with the great majority of patients
having no or minor symptoms. The distribution between
mild and severe cases was similar in UC and CD patients
(p = 0.386).
The mean IBDQ score of the UC patients was 178.5
(Standard deviation, SD = 35.3), while for CD patients
was 177.6 (SD = 39.6); the difference was not statistically
significant (p = 0.892). Similarly, no statistical differences
Table 1: Demographic characteristics of the study population.
Crohn's disease Ulcerative colitis Total
Total number of patients 54 81 135
Age median, years (range) 39 (16–84) 41 (21–84)
<60 42 (77.5%) 62 (76.6%) 104 (77.0%)
≥  60 12(22.5%) 19 (23.4%) 31 (23.0%)
Smoking habits
Never smoked 20 (37.1%) 51 (62.9%) 71 (52.6%)
Ex smoker 10 (18.5%) 17 (20.9%) 27 (20.0%)
Present smoker 24 (44.4%) 13 (16.2%) 37 (27.4%)
Civil status
Married 38 (70.4%) 60 (74.1%) 98 (72.6%)
Single 12 (22.2 %) 14 (17.3%) 26 (19.2%)
Divorced 1 (1.9%) 2 (2.5%) 3 (2.3%)
Widowed 3 (5.5%) 5 (6.1%) 8 (5.9%)
Duration of IBD, years (mean) 6.5 8.4
Disease Activity
Minor symptoms 42 (77.8%) 68 (84%) 110 (81.5%)
Severe symptoms 12 (22.2%) 13 (16%) 25 (18.5%)
Hospitalized 12 (22.2%) 12 (15%) 24 (17.8%)BMC Gastroenterology 2002, 2 http://www.biomedcentral.com/1471-230X/2/1
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were observed in any of the four dimensional IBDQ
scores. Total and dimensional IBDQ scores are presented
in table 2. Very few of the patients scored the worst or best
possible scores, except for the social subscore, in which
44% of the patients scored 34 or 35 (the best possible
score is 35). With respect to SF-36 the mean score of the
UC patients was 73.7 (SD = 14.1), while for CD patients
was 72.7 (SD = 13.7); the difference was not statistically
significant (p = 0.808) and similarly no statistical differ-
ences were observed in all "four dimensional" SF-36
scores.
Patients were classified according age at the time of diag-
nosis into two groups; those who were less than 60 years
old and those who were equal or older than 60 years. The
mean IBDQ score was 178.13 (SD = 37.9) for the young
group and 174.80 (SD = 33.0) for the elderly group. The
results of the two-way analysis with disease and age group
as independent factors, showed in table 3, indicated no
significant difference in IBDQ dimensional scores be-
tween the two disease groups or between the two age
groups. The only exception was the social dimension
where the younger group had significantly higher scores
than the older group (29.7 and 26.0, respectively) and this
difference was more pronounced within the UC group of
patients than the CD (disease by age interaction was sig-
nificant; p = 0.017). Similarly, with respect to SF-36, no
statistical significant differences were observed among the
four dimensional scores between the two age groups, with
the only exception of the social dimension where the
younger group scored better than the older one (p =
0.008).
Table 2: Total and dimensional IBDQ scores (standard deviations in brackets) in the UC and CD group.
Crohn's disease Ulcerative Colitis p value Total
(mean ± SD) (mean ± SD) (t-test) (mean ± SD)
Bowel 58.6 (11.2) 59.1 (10.4) 0.799 58.9 (10.7)
Systemic 27.3 (7.4) 27.9 (6.5) 0.592 27.7 (6.9)
Emotional 63.2 (15.9) 61.9 (15.4) 0.659 62.4 (15.6)
Social 28.5 (8.1) 29.4 (7.1) 0.468 29.1 (7.5)
Total 177.6 (39.6) 178.4 (35.3) 0.892 178.1 (36.9)
Table 3: Comparison of the total and dimensional IBDQ scores between the young (<60) and old (>60) population group.
CD (mean ± SD) UC (mean ± SD) Disease* Age Group* Interaction*
Bowel <60 57.73 ± 11.7 60.06 ± 10.4
0.406 0.741 NS
>60 61.27 ± 9.1 54.92 ± 9.9
Systemic <60 26.90 ± 7.8 28.30 ± 6.4
0.815 0.801 NS
>60 28.27 ± 5.9 26.14 ± 7.1
Emotional <60 61.00 ± 16.6 62.14 ± 15.4
0.205 0.391 NS
>60 69.54 ± 9.7 59.57 ± 14.6
Social <60 28.21 ± 8.4 30.66 ± 6.4
0.346 0.060 0.017
>60 29.09 ± 7.2 23.50 ± 8.1
Total <60 173.76 ± 41.5 181.04 ± 35.3
0.318 0.888 NS
>60 188.18 ± 29.4 164.28 ± 32.8
* P-values for differences between disease, age group and 'disease by age group' interaction derived by two-way analysis of variance; NS: non signif-
icantBMC Gastroenterology 2002, 2 http://www.biomedcentral.com/1471-230X/2/1
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No significant difference regarding HRQoL was observed
between smokers and non-smokers/ex-smokers and this
result was consistent in both disease groups.
Patients were classified into three groups according to dis-
ease duration: a) those who had the disease less than 1
year, b) between 1 and 5 years and c) more than five years
[44]. No significant difference regarding HRQoL was ob-
served between the three duration groups and this result
was consistent in both disease groups.
Of the 135 patients participated in the study according to
the disease activity indexes (HBI for CD, CAI for UC) 110
patients were thought to have minor symptoms and 25
patients as having severe symptoms. The results of the
two-way analysis with disease and disease activity as inde-
pendent factors, showed in table 4, indicated highly sig-
nificant differences in all IBDQ scores between the two
disease activity groups (those with minor symptoms
scored significantly higher than those with severe symp-
toms) and these differences were consistent in both dis-
eases (non-significant interactions). The mean total IBDQ
score was 192 for the 'minor or no' symptoms group and
116 for the 'severe' symptoms group. Analogous results
were observed with the use of the generic SF-36 question-
naire. The mean total SF-36 score was 82.2 for the "minor
or no" symptoms group, while for the "severe" symptoms
group were 70.6 (p = 0.001).
The independent influence of age, gender, disease activity,
duration of disease and smoking on quality of life (as
measured by the IBDQ total score) was studied by multi-
ple linear regression analysis. Three of the independent
variables, gender, disease activity and smoking were cate-
gorical. These variables were transformed appropriately to
dummy variables. The analysis revealed that only disease
activity had a significant effect on quality of life; the dele-
tion of the other variables was not significant (p = 0.954).
It appears that, all other factors staying stable, a patient
changing from "minor symptoms" to "severe symptoms"
level is expected to have an average decrease of about 87
units in his/her quality of life score.
The application of discriminant analysis, for distinguish-
ing patients with minor symptoms from those with se-
vere, revealed that only two IBDQ dimensional sub-scores
had significant discriminating ability (p < 0.001). These
were the bowel and systemic dimensions. The estimate of
Fisher's linear discriminant function (LDF) was:
LDF = - 25.637 + 0.241 * Bowel + 0.544 * Systemic
Table 4: Comparison of HRQoL between patients with minor or severe disease symptoms
CD UC Disease* Disease Activity* Interaction*
(mean ± SD) (mean ± SD)
Bowel minor 62.92 ± 8.1 62.51 ± 6.1
0.410 0.001 NS
severe 43.58 ± 6.9 41.30 ± 10.4
Systemic minor 30.71 ± 3.3 30.00 ± 4.3
0.524 0.001 NS
severe 15.50 ± 5.6 17.46 ± 6.3
Emotional minor 69.66 ± 10.6 69.66 ± 12.6
0.458 0.001 NS
severe 40.41 ± 8.5 40.41 ± 9.9
Social minor 31.92 ± 4.6 31.54 ± 4.9
0.459 0.001 NS
severe 16.58 ± 6.2 18.69 ± 7.1
Total minor 195.21 ± 21.6 190.05 ± 22.7
0.750 0.001 NS
severe 115.83 ± 21.8 117.76 ± 25.7
* P-values for differences between disease group, disease activity and 'disease group by disease activity' interaction derived by two-way analysis of 
variance; NS: non significantBMC Gastroenterology 2002, 2 http://www.biomedcentral.com/1471-230X/2/1
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Using this index and boring in mind that higher scores
correspond to higher quality of life, one can classify pa-
tients with LDF > 0 into the "minor symptoms" group,
and patients with LDF < 0 in the "severe symptoms"
group. On this basis, the whole sample was reclassified by
the leaving-one-out method. Table 5 shows the results;
note that the correct re-classification rate was very high at
94.8%.
Discussion
In this study the IBDQ dimensional scores were high; the
mean total score was greater than 178, showing that our
sample of IBD patients had a relatively good quality of life
[16,17,45,46]. It would be interesting if we could com-
pare these results, with the results coming from another
group of patients with chronic disease, such as rheuma-
toid arthritis. Unfortunately there are no published data,
regarding the Greek population. This study also examined
the relative ability of the four IBDQ dimensional scores in
distinguishing patients with minor or severe symptoms.
Discriminant analysis showed that emotional and social
scores had no significant discriminatory power once the
bowel and systemic symptoms were taken into account.
This is an important observation, which leads to the con-
clusion that in our population of patients the disease se-
verity is associated with HRQoL only in as much as bowel
and systemic dimensions are concerned. The emotional
and social dimensions offer no extra gain in this associa-
tion and should be regarded as indicators of other aspects.
In table 6 the IBDQ dimensional scores are compared
with those from previous HRQoL assessing studies on IBD
patients in the Netherlands and England [19,22]. Our
study shares similar results with the study by Han et al
[22], while DeBoer et al found significantly lower scores
[19]. Several reasons could account for this discrepancy:
First, methodological reasons such as different patients
populations or different conditions under which patients
completed the questionnaire. Cultural reasons concerning
different attitudes and priorities may be a further reason.
Finally, these differences might be due to inclusion of pa-
tients with more severe symptoms.
It is well known and proved in several studies that disease
activity has a great impact on quality of life [8,18–24,47].
Patients with 'severe' symptoms, as expected, scored much
lower than those with 'minor or no' symptoms and there
was a significant difference in every dimensional score of
the questionnaire in the UC and CD patients group, as
well as in the whole population. In patients with relapse
emotional and systemic dimensions were more disturbed.
This demonstrates that patients with IBD suffer from sig-
nificant psychological distress due to their chronic dis-
ease. Such an issue cannot be evaluated by using the
clinical activity indexes only. Drossman et al [47] also
showed using an instrument focused on patients' worries
and concerns that CD patients had a worse quality of life
compared to UC patients. He attributed this finding to
more severe disease, troublesome complications of ster-
oid therapy and to a higher incidence of surgical interven-
tions in CD patients. We however found no differences in
HRQoL between UC and CD patients either with severe or
with minor or no symptoms. The reason for this discrep-
ancy could be ascribed to different instruments used.
It has been reported and disputed that IBD runs a more se-
rious clinical course in older patients [48,49] . A different
clinical course of the disease could have a different impact
on HRQoL. In a large cohort of UC and CD patients from
20 European centres (EC-IBD Study) a similar clinical
course during the first year after manifestation of the dis-
ease was found in young and older patients [50,51]. In
this study, the only difference observed regarding HRQoL
between younger and older patients concerned the social
impairment that was higher in the elderly group. This dif-
ference however could be connected to specific health and
community problems that are related to the elderly per se
and not to IBD.
Table 5: Cross-Validated Count Re-classification results according to discriminant analysis
Predicted Group Membership Total
(according to discriminant analysis)
Minor Severe
Group Membership
(according to disease activity indexes)
Minor 105 5 110
Severe 22 3 2 5
Minor 95.5% 4.5% 100.0%
Severe 8.0% 92.0% 100.0%
c. 94.8% of cross-validated grouped cases correctly classifiedBMC Gastroenterology 2002, 2 http://www.biomedcentral.com/1471-230X/2/1
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It is well known that there is a different pattern of smok-
ing between patients with UC and CD. Smoking is associ-
a t e d  w i t h  a n  i n c r e a s e d  r i s k  f o r  d e v e l o p i n g  C D  a n d  a
decreased risk for developing UC [42], and has a signifi-
cant impact on the course of the disease [36–43]. Al-
though smoking has been reported to have a different
impact on patients with high compared to those with low
disease activity [52] we found no significant difference in
our patients. Although further studies are necessary to an-
alyse fully the correlation between HRQoL and smoking.
Differences in HRQoL observed between patients with
short and long disease duration may be due to more wor-
ries and concerns that patients with a recent diagnosis of
IBD have compared to patients with a long history of IBD.
Patients with a long history of IBD may acquire with time
a better way to cope with their disease, especially when
they experience no frequent relapses [44]. We found no
report on differences in HRQoL in patients with either
short or long history of IBD. In this study no difference in
HRQoL was found among the three groups of patients
concerning disease duration: less than one year, between
one and five years and more than five years.
Multiple regression analysis revealed that only severity of
disease has an independent influence on quality of life.
All other variables recorded in our study were found no
significant. This is an important observation leading to
the conclusion that, at least in Greek IBD patients, disease
activity plays a major role in their perception of quality of
life. Several other variables with a significant impact on
the clinical course of IBD have no important influence on
quality of life.
Table 6 shows the average scores (and standard deviations
in brackets) for all four dimensions and total IBDQ re-
ported by the present study and by two other similar stud-
ies (De Boer et al and Han et al) [19,22]. First, the
comparison between the present study and the one by
Han et al yielded no significant differences in any of the
four dimensions or total score; note however that two di-
mensions, bowel and systemic had marked differences,
failing however to reach statistical significance. In con-
trast, the comparison between this study and the one by
De Boer et al yielded highly significant differences in all
four dimensions and total score.
In conclusion, IBD has a negative impact on HRQoL of
Greek patients although to a lesser degree than has been
previously reported from other countries using IBDQ as
an assessing tool. Patients with higher disease activity had
a more pronounced negative impact on HRQoL. Bowel
and systemic dimensions of the IBDQ were the main de-




1. Hendriksen C, Binder V: Social prognosis in patients with ulcer-
ative colitis. Br Med J 1980, 281:581-583
2. Manousos ON, Giannadaki E, Mouzas : Ulcerative colitis is as
common in Crete as in Northern Europe: A 5-year prospec-
tive study. Eur J Gastroenterol Hepatol 1999, 8:893-898
3. Shivananda S, Lennard-Jones J, Logan R, Fear N, Price A, Carpenter L,
van Blankenstein M: Incidence of inflammatory bowel disease
across Europe: Is there a difference between north and
south? Results of the European Collaborative Study on In-
flammatory Bowel Disease (EC-IBD). Gut 1996, 39:690-697
4. Mallett SJ, Lennard-Jones JE, Bingley J, Gilon E: Living with disease.
Colitis. Lancet 1978, 2:619-621
5. Kjeldsen J, Schaffalitzky de Muckadell OB: Review: assessment of
disease severity and activity in inflammatory bowel disease.
Scand J Gastroenterol 1993, 28:1-9
6. Langholz E, Munkholm P, Davidsen M, Binder V: Colorectal cancer
risk and mortality in patients with ulcerative colitis. Gastroen-
terology 1992, 103:1444-1451
7. Ekbom A, Helmick C, Zack M, Holmberg L, Adami HO: Survival and
causes of death in patients with Inflammatory Bowel Dis-
ease. A population based study. Gastroenterology 1992, 103:954-
60
8. Martin A, Leone L, Fries W, Naccarato R: Quality of life in Inflam-
matory Bowel Disease. Ital J Gastroenterol 1995, 27:450-454
9. Garrett JW, Drossman DA: Health status in Inflammatory Bow-
el Disease. Biological and behavioral considerations. Gastroen-
terology 1990, 99:90-96
10. McMahon AW, Schmitt P, Patterson JF, Rothman E: Personality dif-
ferences between inflammatory bowel disease patients and
their healthy siblings. Psychosom Med 1973, 35:91-103
11. Joachim G, Milne B: The effects of inflammatory bowel disease
on lifestyle. Can Nurse 1985, 34:38-40
12. Latimer PR: Crohn's disease: a review of the psychological and
social outcome. Psychol Med 1978, 8:649-656
13. Lennard-Jones JE: Classification of Inflammatory Bowel Dis-
ease. Scand J Gastroenterol Suppl 1989, 24:2-6
Table 6: IBDQ scores reported in several HRQoL studies
Bowel Systemic Emotional Social Total
(mean ± SD) (mean ± SD) (mean ± SD) (mean ± SD) (mean ± SD)
De Boer et al (n = 271) 37.3 ± 7.7 17.0 ± 4.4 44.9 ± 9.1 20.0 ± 4.7 119.1 ± 22.0
Han et al (n = 30) 54.9 ± 10.4 25.3 ± 5.9 64.1 ± 13.7 29.4 ± 8.1 173.7 ± 33.1
Present study (n = 135) 58.9 ± 10.7 27.7 ± 6.9 62.4 ± 15.6 29.1 ± 7.5 178.1 ± 36.9BMC Gastroenterology 2002, 2 http://www.biomedcentral.com/1471-230X/2/1
Page 8 of 8
(page number not for citation purposes)
Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMedcentral will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Paul Nurse, Director-General, Imperial Cancer Research Fund
Publish with BMC and your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours - you keep the copyright
editorial@biomedcentral.com
Submit your manuscript here:
http://www.biomedcentral.com/manuscript/
BioMedcentral.com
14. Guyatt GH, Mitchell A, Irvine EJ, Singer J, Williams N, Goodacre R,
Tompkins C: A new measure of health status for clinical trials
in Inflammatory Bowel Disease. Gastroenterology 1989, 96:804-
810
15. Irvine EJ: Development and subsequent refinement of the in-
flammatory bowel disease questionnaire: a quality-of-life in-
strument for adult patients with inflammatory bowel
disease. J Pediatr Gastroentrol Nutr 1999, 28:23-27
16. Irvine EJ: Quality of Life-rationale and methods for developing
a disease specific instrument for inflammatory bowel dis-
ease. Scand J Gastroenterol Suppl 1993, 199:22-27
17. Irvine EJ: Quality of Life-measurement in inflammatory bowel
disease. Scand J Gastroenterol Suppl 1993, 199:36-39
18. Pallis AG, Vlachonikolis IG, Mouzas IA: Quality of life of Greek pa-
tients with Inflammatory Bowel Disease. Validation of the
Greek translation of the Inflammatory Bowel Disease Ques-
tionnaire. Digestion 2001, 63:240-246
19. De Boer AG, Wijler W, Bartelsman JFW, de Haes HC: Inflamma-
tory bowel disease questionnaire: cross-cultural adaptation
and further validation. Eur J Gastroenterol Hepatol. 1995, 7:1043-
1050
20. Russel MG, Pastoor CJ, Brandon S, Rijken J, Engels LG, van der Heijde
DM, Stockbrugger RW: Validation of the Dutch translation of
the inflammatory bowel disease questionnaire (IBDQ): a
health-related quality of life questionnaire in inflammatory
bowel disease. Digestion 1997, 58:282-288
21. Cheung WY, Garratt AM, Russell IT, Williams JG: The UK IBDQ –
A British version of the inflammatory bowel disease ques-
tionnaire: development and validation.  J Clin Epidemiol 2000,
53:297-306
22. Han SW, Mc Coll E, Steen N, Barton JR, Welfare MR: The inflam-
matory bowel disease questionnaire: a valid and reliable
measure in ulcerative colitis patients in the north east of
England. Scand J Gastroenterol 1998, 33:961-966
23. Lopez-Vivancos J, Casellas F, Badia X, Vilaseca J, Malagelada JR: Vali-
dation of the Spanish version of the inflammatory bowel dis-
ease questionnaire on ulcerative colitis and Crohn's disease.
Digestion 1999, 60:274-280
24. Kim WH, Cho YS, Yoo HM, Park IS, Park EC, Lim JG: Quality of life
in Korean patients with inflammatory bowel diseases: ulcer-
ative colitis, Crohn's disease and intestinal Behcet's disease.
Int J Colorectal Dis 1999, 14:52-57
25. Irvine EJ: Does self-administration of a quality of life index for
inflammatory bowel disease change the results? J Clin Epidemiol
1996, 49:1177-1185
26. Irvine EJ, Zhou Q, Thompson AK: The short inflammatory bowel
disease questionnaire: a quality of life instrument for com-
munity physicians managing inflammatory bowel disease.
CCRPT Investigators. Canadian Crohn's Relapse Prevention
Trial. Am J Gastroenterol 1996, 91:1571-1578
27. Ware JE, Sherbourne CD: The MOS 36-item Short Form
Health Survey (SF-36). Conceptual framework and item se-
lection. Med Care 1993, 31:247-263
28. McHorney CA, Ware JE, Lu R, Sherbourne CD: The MOS 36-item
Short Form Health Survey (SF-36). III. Test of data quality,
scaling assumptions, and reliability across diverse patient
groups. Med Care 1994, 32:40-66
29. Brazier JE, Harper R, Jones NM, O'Cathain A, Thomas KJ, Usherwood
T, Westlake L: Validating the SF-36 health survey question-
naire: new outcome measure for primary care. Br Med J 1992,
305:160-164
30. Garrat AM, Ruta DA, Abdalla MI, Buckingham JK, Russell IT: The SF-
36 health survey questionnaire: an outcome measure suita-
ble for routine use within the NHS? Br Med J 1993, 306:1440-
1444
31. Harvey RF, Bradshaw JM: A simple index of Crohn's Disease ac-
tivity. Lancet 1980, 8:514
32. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G,
Michelassi F, Hanauer S: Cyclosporine in severe ulcerative coli-
tis refractory to steroid therapy. N Engl J Med 1994, 330:1841-
1845
33. Altman GD: Practical statistics for medical research. London,
UK: Chapman and Hall, 1991
34. Armitage P, Berry G: Statistical methods in medical research.
Oxford, UK: Blackwell Scientific, 1994
35. Lachebruch PA, Mickey MR: Estimation of error rates in discri-
minant analysis. Technometrics, 1968, 10:1-11
36. Jick H, Walker AM: Cigarette smoking and ulcerative colitis. N
Engl J Med 1983, 308:261-263
37. Boyko EJ, Koepsell TD, Perera DR, Inui TS: Risk of ulcerative col-
itis among former and current cigarette smokers. N Engl J Med
1987, 316:707-710
38. Logan RF, Edmond M, Somerville KW, Langman MJ: Smoking and
ulcerative colitis. Br Med J Clin Res 1984, 288:751-753
39. Silverstein MD, Lashner BA, Hanauer SB: Cigarete smoking and
ulcerative colitis: a case control study.  Mayo Clin Proc 1994,
69:425-429
40. Persson PG, Ahlbom A, Hellers G: Inflammatory bowel disease
and tobacco smoke-a case-control study. Gut 1990, 31:1377-
1381
41. Fraga XF, Vergara M, Medina C, Casellas F, Bermejo B, Malagelada JR:
Effects of smoking on the presentation and clinical course of
inflammatory bowel disease.  Eur J Gastroenterol Hepatol 1997,
9:683-687
42. Calkins BM: A meta-analysis of the role of smoking in inflam-
matory bowel disease. Dig Dis Sci 1989, 34:1841-1845
43. Silverstein MD, Lashner BA, Hanauer SB, Evans AA, Kirsner JB: Cig-
arette smoking in Crohn's disease.  Am J Gastroenterol 1989,
84:31-33
44. Hjortswang H, Strom M, Almer S: Health-related quality of life in
Swedish patients with ulcerative colitis. Am J Gastroenterol 1998,
93:2203-2211
45. Irvine EJ: A quality of life index for Inflammatory Bowel Dis-
ease. Can J Gastroenterol 1993, 7:155-159
46. Irvine EJ, Feagan B, Rochon J, Archambault A, Fedorak RN, Groll A,
Kinnear D, Saibil F, McDonald JW: Quality of life: A valid and re-
liable measure of therapeutic efficacy in the treatment of in-
flammatory bowel disease. Gastroenterology 1994, 106:287-296
47. Drossman DA, Patrick DL, Mitchell CM, Zagami EA, Appelbaum MI:
Health related quality of life in IBD. Functional status and pa-
tients' worries and concerns. Dig Dis Sci 1989, 34:1379-1386
48. Akerkar GA, Peppercorn MA: Inflammatory bowel disease in
the elderly. Practical treatment guidelines. Age & Ageing, 1997,
10:199-208
49. Gupta S, Saverymuttu SH, Keshavarzian A, Hodgson HJ: Is the pat-
tern of inflammatory bowel disease different in the elderly?
Age & Ageing, 1985, 14:366-370
50. Mouzas IA, Pallis AG, Vlachonikolis IG, Politi P, Bonanomi A, Butron
M: Minor differences in first manifestation and first-year clin-
ical course of ulcerative colitis between younger and older
patients, Gastroenterology 2001, Suppl; 1222:A-247
51. Mouzas IA, Pallis AG, Vlachonikolis IG, Manousos ON, Bodini P, Tral-
lori G: Symptoms at diagnosis and course during the first year
in Crohn's disease patients do not differ between the young
and the elderly. Gastroenterology 2001, Suppl; 1222:A-247
52. Russel MG, Nieman FH, Bergers JM, Stockbrugger RW: Cigarette
smoking and quality of life in patients with Inflammatory
Bowel Disease. Eur J Gastroenterol Hepatol 1996, 8:1075-1081